I-MAB (IMAB)
1.76
-0.01
(-0.56%)
USD |
NASDAQ |
May 17, 16:00
1.76
0.00 (0.00%)
After-Hours: 20:00
I-MAB Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2020 | 43.17M |
| September 30, 2020 | 37.00M |
| December 31, 2019 | 37.20M |
| Date | Value |
|---|---|
| September 30, 2019 | 44.65M |
| December 31, 2018 | 16.12M |
| September 30, 2018 | 16.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
37.00M
Minimum
Sep 2020
44.65M
Maximum
Sep 2019
40.50M
Average
40.18M
Median
Research and Development Expense (Quarterly) Benchmarks
| Summit Therapeutics Inc | 30.87M |
| Verastem Inc | 17.71M |
| CEL-SCI Corp | 4.628M |
| AIM ImmunoTech Inc | 3.20M |
| IGC Pharma Inc | 0.903M |